Early experience of vascular endothelial growth factor (VEGF) inhibitor in COVID-19 ARDS.

Marwah, Vikas; Choudhary, Robin; Kumar, Tentu Ajai; Peter, Deepu

Marwah, Vikas; Choudhary, Robin; Kumar, Tentu Ajai; Peter, Deepu.

Marwah V; Army Institute of Cardiothoracic Science, Armed Forces Medical College, Pune, India.
Choudhary R; Army Institute of Cardiothoracic Science, Armed Forces Medical College, Pune, India. robinch19@gmail.com.
Kumar TA; Army Institute of Cardiothoracic Science, Armed Forces Medical College, Pune, India.
Peter D; Army Institute of Cardiothoracic Science, Armed Forces Medical College, Pune, India.

Adv Respir Med ; 89(6): 618-620, 2021.

Article in English | MEDLINE | ID: covidwho-1595789

Subject(s)

Bevacizumab/therapeutic use; COVID-19 Drug Treatment; Respiratory Distress Syndrome/drug therapy; Vascular Endothelial Growth Factor A/antagonists & inhibitors; Aged; Humans; Male; Middle Aged; Respiratory Distress Syndrome/virology; Tertiary Care Centers

Keywords

ARDS; Bevacizumab; SARS CoV-2; vascular endothelial growth factor (VEGF)

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / Vascular Endothelial Growth Factor A / Bevacizumab / COVID-19 Drug Treatment Type of study: Case report Limits: Aged / Humans / Male / Middle aged Language: English Journal: Adv Respir Med Year: 2021 Document Type: Article Affiliation country: ARM.a2021.0104

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google